Cassava Sciences (SAVA) said Thursday it has entered into a license agreement with Yale University for intellectual property rights, including an exclusive US method of treatment patent covering simufilam as a potential treatment for seizures linked to rare neurodevelopmental disorders such as tuberous sclerosis complex.
The licensed patent is based on research and development carried out by a neurosurgery professor at Yale, which showed that Cassava's drug candidate, simufilam, reduced TSC-related seizure frequency in animal models.
Shares of Cassava Sciences were up more than 12% in recent Thursday trading.
Price: 2.58, Change: +0.28, Percent Change: +12.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.